|
1
|
Corfield AP: Mucins: A biologically
relevant glycan barrier in mucosal protection. Biochim Biophys
Acta. 1850:236–252. 2015. View Article : Google Scholar
|
|
2
|
Kufe DW: Mucins in cancer: Function,
prognosis and therapy. Nat Rev Cancer. 9:874–885. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rachagani S, Torres MP, Moniaux N and
Batra SK: Current status of mucins in the diagnosis and therapy of
cancer. Biofactors. 35:509–527. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jonckheere N, Skrypek N and Van Seuningen
I: Mucins and tumor resistance to chemotherapeutic drugs. Biochim
Biophys Acta. 1846:142–151. 2014.PubMed/NCBI
|
|
5
|
Beatson RE, Taylor-Papadimitriou J and
Burchell JM: MUC1 immunotherapy. Immunotherapy. 2:305–327. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kimura T and Finn OJ: MUC1 immunotherapy
is here to stay. Expert Opin Biol Ther. 13:35–49. 2013. View Article : Google Scholar
|
|
7
|
Häuselmann I and Borsig L: Altered
tumor-cell glycosylation promotes metastasis. Front Oncol.
4:282014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kaur S, Kumar S, Momi N, Sasson AR and
Batra SK: Mucins in pancreatic cancer and its microenvironment. Nat
Rev Gastroenterol Hepatol. 10:607–620. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Workman HC, Sweeney C and Carraway KL III:
The membrane mucin Muc4 inhibits apoptosis induced by multiple
insults via ErbB2-dependent and ErbB2-independent mechanisms.
Cancer Res. 69:2845–2852. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Valque H, Gouyer V, Gottrand F and Desseyn
JL: MUC5B leads to aggressive behavior of breast cancer MCF7 cells.
PLoS One. 7:e466992012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hoshi H, Sawada T, Uchida M, Saito H,
Iijima H, Toda-Agetsuma M, Wada T, Yamazoe S, Tanaka H, Kimura K,
et al: Tumor-associated MUC5AC stimulates in vivo tumorigenicity of
human pancreatic cancer. Int J Oncol. 38:619–627. 2011.PubMed/NCBI
|
|
12
|
Yamazoe S, Tanaka H, Sawada T, Amano R,
Yamada N, Ohira M and Hirakawa K: RNA interference suppression of
mucin 5AC (MUC5AC) reduces the adhesive and invasive capacity of
human pancreatic cancer cells. J Exp Clin Cancer Res. 29:532010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chauhan SC, Ebeling MC, Maher DM, Koch MD,
Watanabe A, Aburatani H, Lio Y and Jaggi M: MUC13 mucin augments
pancreatic tumorigenesis. Mol Cancer Ther. 11:24–33. 2012.
View Article : Google Scholar
|
|
14
|
Maher DM, Gupta BK, Nagata S, Jaggi M and
Chauhan SC: Mucin 13: Structure, function, and potential roles in
cancer pathogenesis. Mol Cancer Res. 9:531–537. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lakshmanan I, Ponnusamy MP, Das S,
Chakraborty S, Haridas D, Mukhopadhyay P, Lele SM and Batra SK:
MUC16 induced rapid G2/M transition via interactions with JAK2 for
increased proliferation and anti-apoptosis in breast cancer cells.
Oncogene. 31:805–817. 2012. View Article : Google Scholar :
|
|
16
|
Tinder TL, Subramani DB, Basu GD, Bradley
JM, Schettini J, Million A, Skaar T and Mukherjee P: MUC1 enhances
tumor progression and contributes toward immunosuppression in a
mouse model of spontaneous pancreatic adenocarcinoma. J Immunol.
181:3116–3125. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gottfried E, Kreutz M and Mackensen A:
Tumor-induced modulation of dendritic cell function. Cytokine
Growth Factor Rev. 19:65–77. 2008. View Article : Google Scholar
|
|
18
|
Steinman RM: Decisions about dendritic
cells: Past, present, and future. Annu Rev Immunol. 30:1–22. 2012.
View Article : Google Scholar
|
|
19
|
Carlos CA, Dong HF, Howard OM, Oppenheim
JJ, Hanisch FG and Finn OJ: Human tumor antigen MUC1 is chemotactic
for immature dendritic cells and elicits maturation but does not
promote Th1 type immunity. J Immunol. 175:1628–1635. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Monti P, Leone BE, Zerbi A, Balzano G,
Cainarca S, Sordi V, Pontillo M, Mercalli A, Di Carlo V, Allavena
P, et al: Tumor-derived MUC1 mucins interact with differentiating
monocytes and induce IL-10highIL-12low regulatory dendritic cell. J
Immunol. 172:7341–7349. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hiltbold EM, Vlad AM, Ciborowski P,
Watkins SC and Finn OJ: The mechanism of unresponsiveness to
circulating tumor antigen MUC1 is a block in intracellular sorting
and processing by dendritic cells. J Immunol. 165:3730–3741. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rughetti A, Pellicciotta I, Biffoni M,
Bäckström M, Link T, Bennet EP, Clausen H, Noll T, Hansson GC,
Burchell JM, et al: Recombinant tumor-associated MUC1 glycoprotein
impairs the differentiation and function of dendritic cells. J
Immunol. 174:7764–7772. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Freire T, Lo-Man R, Bay S and Leclerc C:
Tn glycosylation of the MUC6 protein modulates its immunogenicity
and promotes the induction of Th17-biased T cell responses. J Biol
Chem. 286:7797–7811. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ishida A, Ohta M, Toda M, Murata T, Usui
T, Akita K, Inoue M and Nakada H: Mucin-induced apoptosis of
monocyte-derived dendritic cells during maturation. Proteomics.
8:3342–3349. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Andrianifahanana M, Moniaux N and Batra
SK: Regulation of mucin expression: Mechanistic aspects and
implications for cancer and inflammatory diseases. Biochim Biophys
Acta. 1765:189–222. 2006.PubMed/NCBI
|
|
26
|
Roy MG, Livraghi-Butrico A, Fletcher AA,
McElwee MM, Evans SE, Boerner RM, Alexander SN, Bellinghausen LK,
Song AS, Petrova YM, et al: Muc5b is required for airway defence.
Nature. 505:412–416. 2014. View Article : Google Scholar :
|
|
27
|
Sóñora C, Mazal D, Berois N, Buisine MP,
Ubillos L, Varangot M, Barrios E, Carzoglio J, Aubert JP and
Osinaga E: Immunohistochemical analysis of MUC5B apomucin
expression in breast cancer and non-malignant breast tissues. J
Histochem Cytochem. 54:289–299. 2006. View Article : Google Scholar
|
|
28
|
Buisine MP, Devisme L, Degand P, Dieu MC,
Gosselin B, Copin MC, Aubert JP and Porchet N: Developmental mucin
gene expression in the gastroduodenal tract and accessory digestive
glands. II Duodenum and liver, gallbladder, and pancreas. J
Histochem Cytochem. 48:1667–1676. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Walsh MD, Clendenning M, Williamson E,
Pearson SA, Walters RJ, Nagler B, Packenas D, Win AK, Hopper JL,
Jenkins MA, et al: Expression of MUC2, MUC5AC, MUC5B, and MUC6
mucins in colorectal cancers and their association with the CpG
island methylator phenotype. Mod Pathol. 26:1642–1656. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Berois N, Varangot M, Sóñora C,
Zarantonelli L, Pressa C, Laviña R, Rodríguez JL, Delgado F,
Porchet N, Aubert JP, et al: Detection of bone marrow-disseminated
breast cancer cells using an RT-PCR assay of MUC5B mRNA. Int J
Cancer. 103:550–555. 2003. View Article : Google Scholar
|
|
31
|
Tiscornia I, Sánchez-Martins V, Hernández
A and Bollati-Fogolín M: Human monocyte-derived dendritic cells
from leukoreduction system chambers after plateletpheresis are
functional in an in vitro co-culture assay with intestinal
epithelial cells. J Immunol Methods. 384:164–170. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lu HP and Chao CC: Cancer cells acquire
resistance to anticancer drugs: An update. Biomed J. 35:464–472.
2012.
|
|
33
|
Anguille S, Smits EL, Lion E, van Tendeloo
VF and Berneman ZN: Clinical use of dendritic cells for cancer
therapy. Lancet Oncol. 15:e257–e267. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hegmans JP and Aerts JG: Immunomodulation
in cancer. Curr Opin Pharmacol. 17:17–21. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pandit TS, Kennette W, Mackenzie L, Zhang
G, Al-Katib W, Andrews J, Vantyghem SA, Ormond DG, Allan AL,
Rodenhiser DI, et al: Lymphatic metastasis of breast cancer cells
is associated with differential gene expression profiles that
predict cancer stem cell-like properties and the ability to
survive, establish and grow in a foreign environment. Int J Oncol.
35:297–308. 2009.PubMed/NCBI
|
|
36
|
Mimeault M, Johansson SL, Senapati S, Momi
N, Chakraborty S and Batra SK: MUC4 down-regulation reverses
chemoresistance of pancreatic cancer stem/progenitor cells and
their progenies. Cancer Lett. 295:69–84. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kalra AV and Campbell RB: Mucin impedes
cytotoxic effect of 5-FU against growth of human pancreatic cancer
cells: Overcoming cellular barriers for therapeutic gain. Br J
Cancer. 97:910–918. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ren J, Agata N, Chen D, Li Y, Yu WH, Huang
L, Raina D, Chen W, Kharbanda S and Kufe D: Human MUC1
carcinoma-associated protein confers resistance to genotoxic
anticancer agents. Cancer Cell. 5:163–175. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Siragusa M, Zerilli M, Iovino F,
Francipane MG, Lombardo Y, Ricci-Vitiani L, Di Gesù G, Todaro M, De
Maria R and Stassi G: MUC1 oncoprotein promotes refractoriness to
chemotherapy in thyroid cancer cells. Cancer Res. 67:5522–5530.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Skrypek N, Duchêne B, Hebbar M, Leteurtre
E, van Seuningen I and Jonckheere N: The MUC4 mucin mediates
gemcitabine resistance of human pancreatic cancer cells via the
Concentrative Nucleoside Transporter family. Oncogene.
32:1714–1723. 2013. View Article : Google Scholar
|
|
41
|
Kalra AV and Campbell RB: Mucin
overexpression limits the effectiveness of 5-FU by reducing
intracellular drug uptake and antineoplastic drug effects in
pancreatic tumours. Eur J Cancer. 45:164–173. 2009. View Article : Google Scholar
|
|
42
|
Nath S, Daneshvar K, Roy LD, Grover P,
Kidiyoor A, Mosley L, Sahraei M and Mukherjee P: MUC1 induces drug
resistance in pancreatic cancer cells via upregulation of multidrug
resistance genes. Oncogenesis. 2:e512013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Patankar MS, Jing Y, Morrison JC, Belisle
JA, Lattanzio FA, Deng Y, Wong NK, Morris HR, Dell A and Clark GF:
Potent suppression of natural killer cell response mediated by the
ovarian tumor marker CA125. Gynecol Oncol. 99:704–713. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Belisle JA, Horibata S, Jennifer GA,
Petrie S, Kapur A, André S, Gabius HJ, Rancourt C, Connor J,
Paulson JC, et al: Identification of Siglec-9 as the receptor for
MUC16 on human NK cells, B cells, and monocytes. Mol Cancer.
9:1182010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Freire T and Osinaga E: The sweet side of
tumor immunotherapy. Immunotherapy. 4:719–734. 2012. View Article : Google Scholar : PubMed/NCBI
|
